Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
Completed · Phase 1
Conditions studied: Intraocular Melanoma, Melanoma (Skin)
In brief
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining monoclonal antibody therapy and vaccine therapy in treating patients who have stage III or stage IV melanoma that has been removed during surgery.
Key facts
- Study ID
- NCT00025181
- Run by
- University of Southern California
- People needed
- 19
- Starts
- 2001-10-01
- Expected to finish
- 2005-06-01
- Last updated by the study team
- 2014-05-22
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.